GlycoMimetics
在场
GlycoMimetics 是一家在股票代码 GLYC (US) 下上市的公司。
涉及GlycoMimetics的并购和融资。
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
高管
查看带有其 22 名主要高管的组织结构图
GlycoMimetics 搜索最多的简介
- Harout Semerjian, Chief Executive Officer
- Patricia Andrews, Director
- Timothy Pearson, Chairman of the Board
创建提醒
跟踪 GlycoMimetics 的高管变动
药店
GlycoMimetics 拥有 1,832 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- Jazz Pharmaceuticals 已收购 Chimerix (公布2025三月6号).
- Cosette Pharmaceuticals has announced the acquisition of Mayne Pharma (公布2025二月25号).
- Bain Capital 已收购 Mitsubishi Tanabe Pharma (公布2025二月12号).
药店 行业的其他推荐联系人
消息
GlycoMimetics 的最新新闻稿
- Press Releases | GlycoMimetics, Inc.
- Press Releases | GlycoMimetics, Inc.
- GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting | GlycoMimetics, Inc.
- GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma | GlycoMimetics, Inc.
- GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint | GlycoMimetics, Inc.
- Press Releases | GlycoMimetics, Inc.
- Press Releases | GlycoMimetics, Inc.
- GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan | GlycoMimetics, Inc.
- GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 | GlycoMimetics, Inc.
- GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) | GlycoMimetics, Inc.
- View more press releases Close
